Can HIV and Hepatitis C Virus Infection be Eliminated Among Persons Who Inject Drugs?

REFERENCES

• Hagan H, Des Jarlais DC. HIV and HCV infection among injecting drug users. Mt Sinai J Med 2000; 67:423–8.
   PubMed Web of Science ®Google Scholar
• Musto D. The American disease: origins of narcotic control. New Haven, CT: Yale University Press, 1973.
   Google Scholar
• CDC. First report of AIDS. In: CDC ed. MMWR weekly report, Vol. 50. Atlanta, GA: Centers for Disease Control, 1981.
   Google Scholar
• Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007; 18:352–8.
   PubMed Web of Science ®Google Scholar
• Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. The Lancet 2008; 372:1733–45.
   PubMed Web of Science ®Google Scholar
• Des Jarlais DC, McKnight C, Arasteh K, et al. Transitions from injecting to non-injecting drug use: potential protection against HCV infection. J Subst Abuse Treat 2014; 46:325–331.
   PubMed Web of Science ®Google Scholar
• Jolley E, Rhodes T, Platt L, et al. HIV among people who inject drugs in Central and Eastern Europe and Central Asia: a systematic review with implications for policy. BMJ Open 2012; 2(5): e0014565.
   Web of Science ®Google Scholar
• Ball A, Des Jarlais DC, Stimson GV. Drug injecting and HIV infection. New York: Routledge, 1998:53–89.
   Google Scholar
• Van Zee A. The promotion and marketing of Oxycontin: commercial triumph, public health tragedy. Am J Public Health. 2009; 99:221–227.
   Google Scholar
• Mars SG, Bourgois P, Karandinos G, Montero F, Ciccarone D. “Every ‘Never'I Ever Said Came True:” Transitions from opioid pills to heroin injecting. Int J Drug Policy 2014; 25:257–66.
   PubMed Web of Science ®Google Scholar
• Valdiserri R, Khalsa J, Dan C, et al. Confronting the emerging epidemic of HCV infection among young injection drug users. Am J Public Health 2014; 104:816–21.
   PubMed Web of Science ®Google Scholar
• Des Jarlais D, Semann S. HIV prevention for injecting drug users: the first 25 years and counting. Psychosom Med 2008; 70:606–11.
   PubMed Web of Science ®Google Scholar
• Vanichseni S, Kitayaporn D, Mastro TD, et al. Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok, Thailand. AIDS 2001; 15:397–405.
   PubMed Web of Science ®Google Scholar
• Eicher A, Crofts N, Benjamin S, Deutschmann P, Roger A. A certain fate: spread of HIV among young in jecting drug users in Manipur, North-East India. AIDS Care 2000; 12:497–504.
   PubMed Web of Science ®Google Scholar
• Bruneau J, Lamothe F, Franco E, et al. High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study. Am J Epidemiol 1997; 146:994–1002.
   PubMed Web of Science ®Google Scholar
• Niccolai LM, Verevochkin SV, Toussova OV, et al. Estimates of HIV incidence among drug users in St. Petersburg, Russia: continued growth of a rapidly expanding epidemic. The European Journal of Public Health 2011; 21:613–9.
   PubMed Web of Science ®Google Scholar
• Uuskula A, Kals M, Rajaleid K, et al. High-prevalence and high-estimated incidence of HIV infection among new injecting drug users in Estonia: need for large scale prevention programs. J Public Health (Oxf) 2008; 30:119–25.
   PubMed Web of Science ®Google Scholar
• Needle RH, Zhao L. HIV Prevention among injecting drug users: strengthening US support for core interventions. Washington, DC: CGHP Center, 2010.
   Google Scholar
• Des Jarlais DC, Friedman SR. HIV infection among intravenous drug users: epidemiology and risk reduction. AIDS (London, England) 1987; 1:67–76.
   Google Scholar
• Des Jarlais DC. The first and second decades of AIDS among injecting drug users. British J Addict 1992; 87:347–53.
   PubMedGoogle Scholar
• Abdul-Quader AS, Feelemyer J, Modi S, et al. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review. AIDS Behav 2013; 17:2878–92.
   PubMed Web of Science ®Google Scholar
• Des Jarlais DC, Feelemyer JP, Modi SN, Abdul-Quader A, Hagan H. High coverage needle/syringe programs for people who inject drugs in low and middle income countries: a systematic review. BMC Public Health 2013; 13:53.
   PubMed Web of Science ®Google Scholar
• Gibson DR, Flynn NM, McCarthy JJ. Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 1999; 13:1807–18.
   PubMed Web of Science ®Google Scholar
• Wood E, Milloy MJ, Montaner JS. HIV treatment as prevention among injection drug users. Current Opinion in HIV and AIDS 2012; 7:151–6.
   PubMed Web of Science ®Google Scholar
• Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. The Lancet 2010; 376:532–9.
   PubMed Web of Science ®Google Scholar
• Wodak A, Maher L. The effectiveness of harm reduction in preventing HIV among injecting drug users. NSW Public Health Bull 2010; 21:69–73.
   PubMedGoogle Scholar
• Stimson GV. AIDS and injecting drug use in the United Kingdom, 1987–1993: the policy response and the prevention of the epidemic. Soc Sci Med 1995; 41:699–716.
   PubMed Web of Science ®Google Scholar
• Des Jarlais DC, Friedman SR, Sotheran JL, et al. Continuity and change within an HIV epidemic: injecting drug users in New York City, 1984 through 1992. JAMA 1994; 271:121–7.
   PubMed Web of Science ®Google Scholar
• Ti L, Kerr T. The impact of harm reduction on HIV and illicit drug use. J Harm Reduction 2014; 11:7.
   PubMed Web of Science ®Google Scholar
• Van den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007; 102:1454–62.
   PubMed Web of Science ®Google Scholar
• Des Jarlais DC, Arasteh K, McKnight C, et al. HIV infection during limited versus combined HIV prevention programs for IDUs in New York City: the importance of transmission behaviors. Drug Alcohol Depen 2010; 109:154–60.
   PubMed Web of Science ®Google Scholar
• Carrieri M, Spire B. Harm reduction and control of HIV in IDUs in France. The Lancet 2008; 372:448.
   PubMed Web of Science ®Google Scholar
• Des Jarlais DC, Perlis T, Arasteh K, et al. “Informed altruism” and “partner restriction” in the reduction of HIV infection in injecting drug users entering detoxification treatment in New York City, 1990–2001. J Acquir Immune Defic Syndr 2004; 35:158–66.
   PubMed Web of Science ®Google Scholar
• Des Jarlais D, Arasteh K, Mcknight C, et al. Combined HIV prevention, the New York City Condom Distribution Program, and the evolution of safer sex behavior among persons who inject drugs in New York City. AIDS and Behav 2014; 18:443–51.
   PubMed Web of Science ®Google Scholar
• Des Jarlais DC, Bramson HA, Wong C, et al. Racial/ethnic disparities in HIV infection among people who inject drugs: an international systematic review and meta-analysis. Addiction 2012; 107:2087–2095.
   PubMed Web of Science ®Google Scholar
• Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20:17–35.
   PubMed Web of Science ®Google Scholar
• Szpakowski JL, Tucker LY. Causes of death in patients with hepatitis B: a natural history cohort study in the United States. Hepatology 2013; 58:21–30.
   PubMed Web of Science ®Google Scholar
• Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284:450–6.
   PubMed Web of Science ®Google Scholar
• Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31:777–82.
   PubMed Web of Science ®Google Scholar
• Freeman AJ, Zekry A, Whybin LR, et al. Hepatitis C prevalence among Australian injecting drug users in the 1970s and profiles of virus genotypes in the 1970s and 1990s. Med J Australia 2000; 172:588–91.
   PubMed Web of Science ®Google Scholar
• Wiessing L, Ferri M, Grady B, et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PloS One 2014; 9:e103345.
   PubMed Web of Science ®Google Scholar
• Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705–14.
   PubMed Web of Science ®Google Scholar
• Lansky A, Finlayson T, Johnson C, et al. Estimating the number of persons who inject drugs in the United States by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS One 2014; 9:e97596.
   PubMed Web of Science ®Google Scholar
• CDC Prevention. Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men—New York City, 2005–2010. MMWR. Morbidity and Mortality Weekly Report 2011; 60:945.
   Google Scholar
• Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312:353–61.
   PubMed Web of Science ®Google Scholar
• Garcia A, Fernandez S, Toro F, De Sanctis JB. An overview of hepatitis C vaccines. Recent Pat Inflamm Allergy Drug Discov 2014; 8:85–91.
   PubMedGoogle Scholar
• Honegger JR, Zhou Y, Walker CM. Will there be a vaccine to prevent HCV infection? Semin Liver Dis 2014; 34:79–88.
   PubMed Web of Science ®Google Scholar
• Liang TJ. Current progress in development of hepatitis C virus vaccines. Nat Med 2013; 19:869–78.
   PubMed Web of Science ®Google Scholar
• Zingaretti C, De Francesco R, Abrignani S. Why is it so difficult to develop a hepatitis C virus preventive vaccine? Clin Microbiol Infect 2014; 20 Suppl 5:103–9.
   Web of Science ®Google Scholar
• Sacks-Davis R, Horyniak D, Grebely J, Hellard M. Behavioural interventions for preventing hepatitis C infection in people who inject drugs: a global systematic review. Int J Drug Policy 2012; 23:176–84.
   PubMed Web of Science ®Google Scholar
• Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis 2011; 204:74–83.
   PubMed Web of Science ®Google Scholar
• MacArthur GJ, van Velzen E, Palmateer N, et al. Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy 2014; 25:34–52.
   PubMed Web of Science ®Google Scholar
• Nolan S, Dias Lima V, Fairbairn N, et al. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction 2014; 109:2053–2059.
   PubMed Web of Science ®Google Scholar
• Des Jarlais DC, Perlis T, Arasteh K, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990–2001. AIDS 2005; 19:S20–5.
   PubMed Web of Science ®Google Scholar
• Martin NK, Vickerman P, Grebely J, et al. HCV treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013; 58:1598–1609.
   PubMed Web of Science ®Google Scholar
• Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013; 57 Suppl 2:S39–45.
   Web of Science ®Google Scholar
• Linas BP, Barter DM, Leff JA, et al. The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLoS One 2014; 9:e97317.
   PubMed Web of Science ®Google Scholar
• Gelberg L, Robertson MJ, Arangua L, et al. Prevalence, distribution, and correlates of hepatitis C virus infection among homeless adults in Los Angeles. Public Health Rep 2012; 127:407–21.
   PubMed Web of Science ®Google Scholar
• Southern WN, Drainoni ML, Smith BD, et al. Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. J Viral Hepat 2011; 18:474–81.
   PubMed Web of Science ®Google Scholar
• Wiessing L, Ferri M, Grady B, et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One 2014; 9:e103345.
   PubMed Web of Science ®Google Scholar
• American Association for the Study of Liver Diseases. Recommendations for testing, managing, and treating hepatitis C. Alexandria, VA: AASLD, 2015.
   Google Scholar
• Aspinall EJ, Corson S, Doyle JS, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Inf Dis 2013; 57:S80–9.
   PubMed Web of Science ®Google Scholar
• Grebely J, Dore GJ. Can hepatitis C virus infection be eradicated in people who inject drugs? Antiviral Res 2014; 104:62–72.
   PubMed Web of Science ®Google Scholar
• Masson CL, Delucchi KL, McKnight C, et al. A randomized trial of a hepatitis care coordination model in methadone maintenance treatment. Am J Pub Health 2013; 103(10):e81–8.
   PubMed Web of Science ®Google Scholar
• UNAIDS, The World Bank, World Health Organization. The global economic crisis and HIV prevention and treatment programmes: vulnerabilities and impact. UNAIDS. Geneva, Switzerland, 2009.
   Google Scholar
• Strathdee SA, Shoptaw S, Dyer TP, Quan VM, Aramrattana A. Towards combination HIV prevention for injection drug users: addressing addictophobia, apathy, and inattention. Curr Opin HIV AIDS 2012; 7:320–5.
   PubMed Web of Science ®Google Scholar